Order ARA-290 for Clinics

ARA-290 (also known by its investigational name cibinetide) is a synthetic 11-amino-acid peptide derived from the tissue-protective helix-B region of erythropoietin (EPO). It was engineered to retain EPO’s anti-inflammatory and tissue-protective signaling while removing the erythropoietic activity that stimulates red blood cell production. It is used in professional and laboratory settings where researchers are evaluating inflammation, nerve repair, or related investigational workflows. Licensed clinics and research accounts can order ARA-290 for practice or laboratory use, with careful attention to professional documentation, form verification, storage, and safety review. It has no FDA-approved human indication for general use, so accounts should treat ARA-290 as an investigational research peptide rather than a retail wellness supplement.

Before adding ARA-290 to inventory, define who will evaluate the product, how it fits the research or clinic protocol, and what records must be retained for purchasing, receipt, storage, and use. Product names in the broader market may refer to powders, lyophilized vials, or reconstituted solutions, but the account should match the active ingredient, quantity, sterility status, and packaging to the current item record before use.

How Clinics and Labs Can Order ARA-290

Ordering ARA-290 should begin with a professional-use or research-use assessment, not a consumer-style purchase. The account should identify the medical director, principal investigator, or supervising professional responsible for product evaluation, the staff member responsible for receiving inventory, and the internal protocol that explains why the peptide is being considered.

MedWholesaleSupplies serves licensed clinical and research accounts, so account records and practice-use context may be reviewed before an order proceeds. For broader peptide procurement, the Peptides category can help teams evaluate adjacent items, but each peptide still requires its own individual review.

Risk Framework and Safety Considerations

Questions about ARA-290’s effects in humans cannot be answered from approved labeling because there is no FDA-approved human label for general use. ARA-290 has been evaluated in Phase 2 human trials for sarcoidosis-associated small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug designation for the former, but development has not progressed to approval and its original sponsor ceased operations. Accounts should use a conservative risk framework, especially for any research involving live subjects, and should have institutional review or biosafety oversight in place before proceeding.

Why it matters: Phase 2 trial signals and orphan-drug designation do not replace informed consent (where applicable), institutional review, or adverse-event planning.

Forms, Strengths, and Product Verification

ARA-290 is marketed across the wider peptide space using terms such as ARA-290 powder, ARA-290 vial, cibinetide, ARA-290 14mg, and reconstituted ARA-290. Those descriptions should not be treated as confirmation of the format available for this item. The account should verify the active ingredient, form, quantity, purity (HPLC/COA), sterility status, and packaging against the current product record and supplier documents.

Storage, Handling, and US Logistics

Storage instructions should come from the product label, certificate of analysis, or distributor documentation. Peptides may be sensitive to heat, light, moisture, or reconstitution technique, so accounts should avoid assumptions based on another brand, compound, or market format.

Receiving staff should inspect packaging before releasing ARA-290 into inventory. Match the item to the purchase record, record lot and expiry information, note package condition, and place the product in the required storage environment (typically frozen or refrigerated, protected from light). For operational planning, accounts should factor in temperature-controlled handling and tracked US delivery requirements.

Related Peptides

Accounts evaluating ARA-290 alongside related tissue-repair or anti-inflammatory research compounds, or other investigational peptides in the Peptides category, should assess each item separately — combination or comparative research still requires individual documentation, sourcing verification, and risk review for every active ingredient involved.